BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 31252403)

  • 1. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives.
    Ceolin L; Duval MADS; Benini AF; Ferreira CV; Maia AL
    Endocr Relat Cancer; 2019 Aug; 26(9):R499-R518. PubMed ID: 31252403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
    Dabelić N; Jukić T; Fröbe A
    Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic treatment and management approaches for medullary thyroid cancer.
    Ernani V; Kumar M; Chen AY; Owonikoko TK
    Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medullary thyroid cancer: a promising model for targeted therapy.
    Torino F; Paragliola RM; Barnabei A; Corsello SM
    Curr Mol Med; 2010 Oct; 10(7):608-25. PubMed ID: 20712590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.
    Chu YH; Lloyd RV
    Endocr Pathol; 2016 Dec; 27(4):312-324. PubMed ID: 27539727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.
    Hedayati M; Zarif Yeganeh M; Sheikholeslami S; Afsari F
    Crit Rev Clin Lab Sci; 2016 Aug; 53(4):217-27. PubMed ID: 26678667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New drugs for medullary thyroid cancer: new promises?
    Spitzweg C; Morris JC; Bible KC
    Endocr Relat Cancer; 2016 Jun; 23(6):R287-97. PubMed ID: 27185870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precision Targeted Therapy with BLU-667 for
    Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
    Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances and controversies in the management of medullary thyroid carcinoma.
    Maia AL; Wajner SM; Vargas CV
    Curr Opin Oncol; 2017 Jan; 29(1):25-32. PubMed ID: 27792051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Advanced Medullary Thyroid Carcinoma: Current Systemic Therapy Options.
    Jara MA
    Crit Rev Oncog; 2024; 29(3):83-90. PubMed ID: 38683155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma.
    Raue F; Frank-Raue K
    Recent Results Cancer Res; 2015; 204():61-90. PubMed ID: 26494384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medullary thyroid carcinoma in children: current state of the art and future perspectives.
    Kiriakopoulos A; Dimopoulou A; Nastos C; Dimopoulou D; Dimopoulou K; Menenakos E; Zavras N
    J Pediatr Endocrinol Metab; 2022 Jan; 35(1):1-10. PubMed ID: 34592078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma.
    Almeida MQ; Hoff AO
    Curr Opin Oncol; 2012 May; 24(3):229-34. PubMed ID: 22343387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAS proto-oncogene in medullary thyroid carcinoma.
    Moura MM; Cavaco BM; Leite V
    Endocr Relat Cancer; 2015 Oct; 22(5):R235-52. PubMed ID: 26285815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
    Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C
    Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma.
    Santarpia L; Ye L; Gagel RF
    J Intern Med; 2009 Jul; 266(1):99-113. PubMed ID: 19522829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the Treatment of Medullary Thyroid Carcinoma in Patients with Multiple Endocrine Neoplasia Type 2.
    Ilanchezhian M; Khan S; Okafor C; Glod J; Del Rivero J
    Horm Metab Res; 2020 Aug; 52(8):588-597. PubMed ID: 32299110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve
    Wirth LJ; Brose MS; Elisei R; Capdevila J; Hoff AO; Hu MI; Tahara M; Robinson B; Gao M; Xia M; Maeda P; Sherman E
    Future Oncol; 2022 Sep; 18(28):3143-3150. PubMed ID: 35969032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
    Dadu R; Hu MN; Grubbs EG; Gagel RF
    Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on Targeted Therapy in Medullary Thyroid Cancer.
    Okafor C; Hogan J; Raygada M; Thomas BJ; Akshintala S; Glod JW; Del Rivero J
    Front Endocrinol (Lausanne); 2021; 12():708949. PubMed ID: 34489865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.